The first meningococcal A conjugate vaccine, introduced nationwide in Burkina Faso on 6 December 2010, is expected to eliminate the primary cause of epidemic meningitis in Africa, if introduced in all 25 countries of what has become known as the "meningitis belt".
Designed specifically to protect against group A meningococcus, which accounts for 80-85% of cases of meningitis in the 25 countries of the African "meningitis belt", the vaccine is priced than US$ 0.50 per dose, and cost less than one-tenth of the US$ 500 million usually required to develop and bring a vaccine to market.
The vaccine was developed by the Meningitis Vaccine Project — a partnership between WHO and the international non-profit PATH, working closely with public health officials in countries of the meningitis belt, and research institutions across the world. It was manufactured by an Indian company, which agreed from the outset to accept technology transfer from companies with expertise in vaccine conjugation, and to sell the vaccine at a price affordable for African countries.
Link this story to your website:
Copy the above code and paste it into your webpage, blog or forum
Be the first one to comment on this news